Abstracts tagged "Natural Killer Cells"

Abstract Number: 0291 • ACR Convergence 2020
SLAMF7 and CD38 on NK Cells Represent Potential New Therapeutic Targets for Systemic Lupus Erythematosus
Morgane Humbel¹, Florence Bellanger², Craig Fenwick², Alice Horisberger², Camillo Ribi² and Denis Comte², ¹CHUV, Lausanne, Vaud, Switzerland, ²CHUV, Lausanne, Switzerland
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by the production of autoantibodies. For this reason, anti-B cell therapy seems to be…
Abstract Number: 0473 • ACR Convergence 2020
Characterization of DOCK8 as a Novel Gene Associated with Cytokine Storm Syndrome
Mingce Zhang¹, Remy Cron², Devin Absher³, Prescott Atkinson¹, Winn Chatham¹ and Randy Cron¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, ³HudsonAlpha Institute for Biotechnology, Huntsville, AL
Background/Purpose: Cytokine storm syndrome (CSS), also known as macrophage activation syndrome (MAS) or secondary hemophagocytic lymphohistiocytosis (HLH), is a life threatening condition that commonly presents…
Abstract Number: 1575 • ACR Convergence 2020
CD6 Is a Target for Cancer Immunotherapy
Jeffrey Ruth¹, Mikel Gurrea Rubio², Kalana Athukorala³, Stephanie Rasmussen¹, Weber Daniel¹, Peggy Randon¹, M Asif Amin¹, Phillip Campbell¹, Pei-suen Tsou¹, Yang Mao-Draayer¹, Qi Wu⁴, Matthew Lind¹, Rosemary Gedert¹, Thomas Lanigan¹, Venkateshwar Keshamouni¹, Nora Singer⁵, Feng Lin⁶ and David Fox⁷, ¹University of Michigan, Ann Arbor, MI, ²Division of Rheumatology, University of Michigan, Canton, MI, ³University of Michigan, Ann Arbor, MN, ⁴University of Michigan, Ann Arbor, ⁵The MetroHealth System, Case Western Reserve University School of Medicine, Cleveland, OH, ⁶Cleveland Clinic Foundation, Cleveland, OH, ⁷Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Limitations of checkpoint inhibitor immunotherapy include induction of autoimmune syndromes and resistance of many cancers. Definition of additional molecular targets is required. CD6, expressed…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].